Oct 10 (Reuters) - Eli Lilly and Co said on Tuesday its drug to treat non-small cell lung cancer failed to meet the main goal of improving overall survival in patients in a late-stage study.
Lilly's abemaciclib, however, showed some evidence of improvement in the secondary goals, the company said. (Reporting by Divya Grover in Bengaluru; Editing by Maju Samuel)
Walmart's CEO went from earning $6.50 an hour to $25 million a year—here are his three tips for climbing the corporate ladder like him
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
These proven wealth builders could be exactly what you're searching for right now.
The property report includes 85 major metropolitan areas in the U.S. with populations of at least 750,000.
Here's what could happen next to Microsoft shares.
"We are not very ambitious. I should be careful about talking about work-life balance, but the Americans just work harder.”
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
It's been an "everything buy bonds" bull rally in markets for months, but BofA is cautiously watching a couple of indicators.
Jamie Dimon and Jerome Powell are taking the European viewpoint on soaring debt levels in the U.S.
It's possible to construct a winning long-term investment strategy with just low-cost index funds.